Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PAHC 
Phibro Animal Health Corporation (PAHC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/26/2025: PAHC (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 27.38% | Avg. Invested days 46 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 03/26/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 889.86M USD | Price to earnings Ratio 45.77 | 1Y Target Price 20.75 |
Price to earnings Ratio 45.77 | 1Y Target Price 20.75 | ||
Volume (30-day avg) 298692 | Beta 0.58 | 52 Weeks Range 12.02 - 26.42 | Updated Date 04/1/2025 |
52 Weeks Range 12.02 - 26.42 | Updated Date 04/1/2025 | ||
Dividends yield (FY) 2.25% | Basic EPS (TTM) 0.48 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 1.75% | Operating Margin (TTM) 11.64% |
Management Effectiveness
Return on Assets (TTM) 5.6% | Return on Equity (TTM) 7.46% |
Valuation
Trailing PE 45.77 | Forward PE 10.57 | Enterprise Value 1612254266 | Price to Sales(TTM) 0.8 |
Enterprise Value 1612254266 | Price to Sales(TTM) 0.8 | ||
Enterprise Value to Revenue 1.46 | Enterprise Value to EBITDA 15.91 | Shares Outstanding 20337600 | Shares Floating 20167556 |
Shares Outstanding 20337600 | Shares Floating 20167556 | ||
Percent Insiders 0.59 | Percent Institutions 107.63 |
Analyst Ratings
Rating 2.4 | Target Price 19.4 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 2 | Sell 3 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Phibro Animal Health Corporation
Company Overview
History and Background
Phibro Animal Health Corporation was founded in 1916 as Philipp Brothers. Originally a mineral trading company, it evolved into a focused animal health company. In 2014, Phibro completed its initial public offering (IPO).
Core Business Areas
- Animal Health: Develops, manufactures, and markets a broad range of animal health and nutritional products for livestock, including poultry, swine, cattle, and aquaculture.
- Nutritional Specialties: Provides specialty ingredients for animal feed, designed to improve animal performance and enhance feed quality.
- Performance Alternatives: Offers alternatives to antimicrobials, with a focus on products designed to promote animal health and performance in a sustainable manner.
Leadership and Structure
Jack Bendheim serves as the Chairman of the Board, and Damien H. McDonald is the Chief Executive Officer. The company operates with a global organizational structure, with regional teams managing sales and operations in key markets.
Top Products and Market Share
Key Offerings
- Medicated Feed Additives: Antibiotics and other medications added to animal feed to prevent or treat diseases and promote growth. Competitors include Zoetis, Elanco, and Merck Animal Health. Market share information is fragmented and varies by specific product and region, but Phibro holds a significant position, particularly in certain antibiotic alternatives. Revenue information is not publicly broken down per product.
- Nutritional Specialty Products: Yeast and mineral-based products added to animal feed to improve animal health and performance. Competitors include Alltech, ADM, and Cargill. Market share data is similarly fragmented. Again, revenue data is not publicly broken down per product.
- Vaccines: Range of vaccines that prevent and treat various conditions in animals. The competitors for this product are Zoetis, Elanco, and Merck Animal Health. Market share information is fragmented and varies by specific product and region, but Phibro holds a significant position, particularly in certain antibiotic alternatives. Revenue information is not publicly broken down per product.
Market Dynamics
Industry Overview
The animal health industry is driven by the increasing global demand for meat, milk, and eggs, as well as the growing awareness of animal welfare and disease prevention. The industry is also shaped by increasing regulation and the need for sustainable production practices.
Positioning
Phibro is positioned as a key player in the animal health industry, with a strong focus on developing and marketing innovative products that improve animal health, performance, and sustainability. Its competitive advantages include its global reach, its diverse product portfolio, and its expertise in animal nutrition.
Total Addressable Market (TAM)
The global animal health market is estimated to be over $50 billion USD. Phibro is positioned to capture a significant share of this market through its product portfolio and global reach.
Upturn SWOT Analysis
Strengths
- Established global presence
- Diverse product portfolio
- Strong relationships with key customers
- Expertise in animal nutrition
- Focus on innovation
Weaknesses
- Dependence on regulatory approvals
- Exposure to commodity price fluctuations
- Limited brand recognition compared to larger competitors
- Highly fragmented market
Opportunities
- Increasing demand for animal protein in developing countries
- Growing awareness of animal welfare and disease prevention
- Development of new technologies for animal health
- Expansion into new markets
- Acquisition of complementary businesses
Threats
- Increased competition from larger players
- Changes in government regulations
- Emergence of new animal diseases
- Economic downturns
- Public perception of animal agriculture
Competitors and Market Share
Key Competitors
- ZTS
- ELAN
- MRK
Competitive Landscape
Phibro faces competition from larger, more established players like Zoetis, Elanco, and Merck Animal Health. While it is more agile and focused, but these larger companies have the benefits of scale. Phibro differentiates itself through its niche product offerings and customer relationships.
Major Acquisitions
Abic Biological Laboratories Ltd.
- Year: 2016
- Acquisition Price (USD millions): 77.4
- Strategic Rationale: Expanding vaccine development and manufacturing capabilities, particularly in poultry.
Growth Trajectory and Initiatives
Historical Growth: Phibro's historical growth has been driven by a combination of organic growth and acquisitions. Expansion into new markets and product development have contributed to this growth.
Future Projections: Analyst estimates suggest continued growth for Phibro, driven by increasing demand for animal protein and the company's strategic initiatives. However, these projections are subject to market risks and uncertainties.
Recent Initiatives: Recent initiatives include expanding its presence in key markets, developing new products and technologies, and making strategic acquisitions.
Summary
Phibro Animal Health Corporation is a well-positioned player in the animal health market with a diverse product portfolio and global reach. The company's strategic initiatives, including acquisitions and product development, have helped drive growth. However, Phibro faces increasing competition from larger players and is exposed to regulatory and market risks. While they are in a fragmented industry, they continue to compete with the top animal health organizations.
Similar Companies
ELAN
Elanco Animal Health
ELAN
Elanco Animal Health
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
ZTS
Zoetis Inc
ZTS
Zoetis Inc
Sources and Disclaimers
Data Sources:
- Phibro Animal Health Corporation Investor Relations
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered as financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Phibro Animal Health Corporation
Exchange NASDAQ | Headquaters Teaneck, NJ, United States | ||
IPO Launch date 2014-04-11 | Chairman, President & CEO Mr. Jack Clifford Bendheim | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1940 | Website https://www.pahc.com |
Full time employees 1940 | Website https://www.pahc.com | ||
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.